Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma.

Szczegóły
Abstrakt

Tytuł:: Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma.
Autorzy:: Bukhari N; Department of Medical Oncology, King Fahad Specialist Hospital, Dammam, SAU.; Department of Internal Medicine, Imam Abdulrahman Bin Faisal University, Dammam, SAU.
Abdalla K; Department of Medical Oncology, King Fahad Specialist Hospital, Dammam, SAU.
Ibnshamsa F; Department of Medical Oncology, King Fahad Specialist Hospital, Dammam, SAU.
Alselwi W; Department of Medical Oncology, King Fahad Specialist Hospital, Dammam, SAU.
Al-Shakir S; Department of Radiation Oncology, King Fahad Specialist Hospital, Dammam, SAU.
Alqahtani M; Multiorgan Transplant Center, King Fahad Specialist Hospital, Dammam, SAU.
Źródło:: Cureus [Cureus] 2021 Oct 13; Vol. 13 (10), pp. e18756. Date of Electronic Publication: 2021 Oct 13 (Print Publication: 2021).
Typ publikacji:: Case Reports
Język:: English
Imprint Name(s):: Original Publication: Palo Alto, CA : Cureus, Inc.
References:: Lancet. 2016 Jul 2;388(10039):73-85. (PMID: 26830752)
Br J Cancer. 2015 Sep 29;113(7):989-95. (PMID: 26372701)
N Engl J Med. 2011 May 12;364(19):1817-25. (PMID: 21561347)
Case Rep Oncol. 2019 Sep 25;12(3):728-736. (PMID: 31616281)
Acta Oncol. 2016;55(3):265-77. (PMID: 26213211)
J Clin Oncol. 2020 Jan 1;38(1):1-10. (PMID: 31682550)
Clin Cancer Res. 2018 Mar 15;24(6):1344-1354. (PMID: 29288237)
J Clin Med. 2019 May 29;8(6):. (PMID: 31146420)
Clin Cancer Res. 2020 Jul 1;26(13):3239-3247. (PMID: 32444418)
Acta Gastroenterol Belg. 2017 Oct-Dec;80(4):451-461. (PMID: 29560639)
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861. (PMID: 30487695)
Mod Pathol. 2020 Jan;33(1):38-46. (PMID: 31375766)
N Engl J Med. 2013 Oct 31;369(18):1691-703. (PMID: 24131140)
Case Rep Oncol. 2017 Jun 29;10(2):577-581. (PMID: 28868015)
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii36-viii40. (PMID: 31605106)
Am J Case Rep. 2019 Apr 26;20:597-601. (PMID: 31023997)
Lancet. 2016 Feb 6;387(10018):545-557. (PMID: 26615328)
Nat Genet. 2015 Oct;47(10):1168-78. (PMID: 26343385)
N Engl J Med. 2018 Feb 22;378(8):731-739. (PMID: 29466156)
N Engl J Med. 2019 Jul 25;381(4):317-327. (PMID: 31157963)
Ther Adv Med Oncol. 2020 May 27;12:1758835920923424. (PMID: 32523632)
Gut. 2017 Sep;66(9):1665-1676. (PMID: 27325420)
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):934-947. (PMID: 31648972)
Contributed Indexing:: Keywords: chemotherapy; folfirinox; gemcitabine; nab-paclitaxel; pancreatic cancer
Entry Date(s):: Date Created: 20211119 Latest Revision: 20211120
Update Code:: 20240105
PubMed Central ID:: PMC8589452
DOI:: 10.7759/cureus.18756
PMID:: 34796055
: Raport

Pancreatic cancer is an extremely lethal malignancy with the majority of patients presenting with advanced disease. Typically, fit patients with advanced unresectable disease are treated with chemotherapy, which comprises either first-line folfirinox (FNX) or gemcitabine/nab-paclitaxel (GNP) regimens based on level 1 evidence. To our knowledge, robust evidence for second-line GNP post FNX does not exist. We herein report four cases treated at our institute with second-line GNP. Amongst those were patients with durable responses lasting over a year, which is extremely rare in stage 4 pancreatic cancer.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2021, Bukhari et al.)

Informacja